HC Wainwright reiterated their buy rating on shares of OPKO Health (NASDAQ:OPK – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. The brokerage currently has ...

(Reuters) -OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other ...

Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral ...

OPKO Health (NASDAQ: OPK) has recently received a number of price target changes and ratings updates: 3/19/2025 – OPKO Health had its “buy” rating reaffirmed by analysts at HC Wainwright. They now ...

OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

In a regulatory filing, Opko Health (OPK) disclosed that its CEO Phillip Frost bought 200K shares of common stock on March 17th in a total ...

Opko Health and Entera Bio entered into a collaboration and license agreement to advance a tablet aimed at addressing obesity, metabolic and fibrotic disorders.

Vertical Aerospace • EVTL-NYSE Buy • $3.39 on March 12 by Canaccord Genuity We are maintaining our Buy rating on shares of ...

Labcorp will acquire BioReference Health's oncology diagnostics operations as the lab company works to expand in high-growth ...

OPKO Health (OPK) and Entera Bio (ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a ...